Mirtazapine Eg

Mirtazapine, the active ingredient in Mirtazapine Eg, is a tetracyclic antidepressant presented as an oral formulation for oral use. It is indicated for the treatment of major depressive disorder in adult patients, helping to improve mood and functional outcomes.

GNH USA supplies Mirtazapine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across multiple regions.

Mirtazapine is a tetracyclic antidepressant used primarily in the management of depressive disorders.

Major depressive disorder: alleviates depressive symptoms and improves overall mood. Depression with insomnia: may enhance sleep quality while treating depressive symptoms. Depression with anxiety: can reduce anxiety components associated with depressive episodes.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Hepatic dysfunction (jaundice, elevated enzymes) - Hyponatremia - Suicidal thoughts or worsening depression - Severe allergic reactions (rash, angioedema)

Before initiating therapy, consider the following precautions.

Pregnancy: safety not established; use only if benefits outweigh risks. Elderly patients: increased sensitivity to sedation and weight gain. Liver impairment: dose adjustment may be required. Concurrent CNS depressants: may enhance sedative effects. Monitor for mood worsening or emergent suicidal ideation. Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increased mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may increase anticholinergic burden. - Diuretics: potential electrolyte disturbances. - Lithium: monitor lithium serum concentrations.